Abeona Reports Updated Data from Gene Therapy for EB

Abeona Therapeutics reports updated clinical data from the phase 1/2 trial for EB-101, the company’s gene-corrected skin graft cell therapy for patients suffering from recessive dystrophic epidermolysis bullosa.

Read More  >